pISSN 1226-6051
eISSN 2508-786X

Fig. 1.

Download original image
Fig. 1. Changes and trends in blood glucose and duration of pembrolizumab administration in (A) all patients and (B) subgroup patients of no history of diabetes and concomitant medications with baseline random glucose level under 130 mg/dL and (C) over 130 mg/dL
Korean J Clin Pharm 2021;31:237-46 https://doi.org/10.24304/kjcp.2021.31.3.237
© 2021 Korean J Clin Pharm